<DOC>
	<DOCNO>NCT01028859</DOCNO>
	<brief_summary>A phase I study conducted determine maximum tolerate dose ( MTD ) , dose limit toxicity ( DLT ) , safety pharmacokinetics ( PK ) profile single agent CKD-516 injection weekly schedule patient advance solid cancer fail standard therapy . The usefulness regimen evaluate response rate , progression free survival vascular disruption effect Dynamic Contrast-Enhanced MRI ( DCE-MRI ) .</brief_summary>
	<brief_title>Safety Study Increasing Doses CKD-516 Patients With Advanced Solid Cancers</brief_title>
	<detailed_description>OBJECTIVES : - I . Determine maximum tolerate dose CKD-516 administer single dos every 21 day patient advance solid tumor . - II . Determine toxicity dose limit toxicity regimen patient . - III . Determine plasma urine pharmacokinetics CKD-516 . - IV . Gather preliminary data regard possible antitumor effect patient measurable diseae . Assess effect CKD-516 tumor blood flow use DCE-MRI scan technique , establish dose effect occur . OUTLINE : This open label , dose escalation study . Patients receive CKD-516 IV 30 minute day 1 , 8 every 3 week absence unacceptable toxicity disease progression . Cohorts 3~6 patient receive escalate dos CKD-516 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity .</detailed_description>
	<criteria>20~75 year Histologically cytologically confirm solid tumor fail standard therapy life prolong treatment exist ECOG PS 02 Life expectancy 12 week Hematopoietic : ANC ≥ 1,500/mm3 , Platelet ≥ 100,000/mm3 , Hemoglobin ≥ 9.0g/dL , Prothrombin time , Activated partial thromboplastin time : normal range Hepatic : total bilirubin ≤ 1.5×ULN ( except Gilbert 's syndrome patient ) , AST , ALT ≤ 3.0×ULN ( AST , ALT ≤ 5.0×ULN case liver metastasis ) Renal : serum creatinine ≤ 1.5×ULN Creatinine clearance ≥ 60 mL/min Signed write informed consent Brain Leptomeningeal metastases History Ischemic heart disease ( e.g. , myocardial infarction , unstable angina pectoris ) Clinically significant heart disease NYHA Class III IV Congestive atrial arrhythmia , within 6 month prior first dose study drug Stable angina pectoris show symptom within 6 month prior first dose study durg , Clinically significant abnormality EKG echocardiogram ( e.g. , LVEF &lt; 50 % clinically significant heart wall abnormality heart muscle damage ) Cerebrovascular disease stroke Grade 2 great motor sensory peripheral neuropathy Clinically significant eye disease ( e.g. , Glaucoma Proliferative diabetic retinopathy , Atrophic macular degeneration ) , clinically significant abnormality screen visit Uncontrolled hypertension ( great 150 mmHg systolic anc 100 mmHg diastolic regardless medication ) acute infection blooding tendency would preclude study compliance Serious vascular disease Aortic aneurysm Other psychiatric disorder condition would preclude study compliance Receiving anticoagulation warfarin , heparin , etc . Receiving antitumor therapy ( surgery , immunotherapy chemotherapy ) within 4 week prior first dose study drug ( 6 week nitrosoureas mitomycin C , 2 week radiation therapy ) Other concurrent antitumor therapy History Serious hypersensitivity allergy Pregnant nursing , active serum pregnancy test . Fertile patient must use effective contraception Participation clinical trial within 4 week first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Tubulin polymerization inhibitor</keyword>
	<keyword>CKD-516</keyword>
	<keyword>Phase I</keyword>
	<keyword>Vascular disrupting agent</keyword>
	<keyword>DCE MRI</keyword>
</DOC>